The most exciting and promising new direction of cancer research is into the body's own natural defense systems against cancer.
Most cancer experts believe we all develop cancer hundreds if not millions of times in our lifetimes. Given the trillions of developing cells, the millions of errors that can occur in the differentiating (maturing) process of each cell, and our constant exposure to carcinogenic substances (smoke, car fumes, radiation, etc.), the laws of probability dictate that mis-developing cells must occur frequently in the life of each individual. It stands to reason that a healthy body has a corrective system to reprogram newly-developed cancer cells into normal differentiation pathways before the cancer can take hold.
Cancer cells differ from healthy cells in that they are, in effect, immortal. While healthy cells live a short while and then die, cancer cells continue dividing. The program for cell death is never activated.
Antineoplastons are peptides, small proteins and amino-acid derivatives found naturally in human blood. Cancer patients tend to have low levels -- as little as 2% that of healthy individuals. Antineoplastons work by reprogramming cancer cells to die like normal cells. Healthy cells are not affected.
Antineoplastons have a two-pronged mechanism of activity. They suppress the activity of the oncogenes that cause cancer, while at the same time stimulating the activity of the tumor-suppressor genes that stop cancer.
Antineoplastons A10 and AS2-1 seem particularly effective against brain cancer and non-hodgkins lymphoma.
Go to Burzynski Research Institute Website